Quarterly report · Q2
4671.TEDINET S100PKQ2
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥24.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥50.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥24.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥38.7bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥40.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥39.1bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.4bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥16.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥24.3bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥23.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥22.4bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.9bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥249m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥503m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥937m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥107.5 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.16 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥339 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥204.38 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥122.9 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥107.18 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥336.99 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥203.77 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 62.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.1% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥213m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥16.2bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥16.2bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥320m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥24.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥24.2bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥8m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥8m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥177m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥16.6bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥16.6bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥7m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥8.1bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥8.1bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥523m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥24.7bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥24.7bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥3.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 519
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)ＰｗＣ 京 都 監 査 法 人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)松 永 幸 廣 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)浦 上 卓 也 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 24693000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 24151000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 50007000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 3342000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 1877000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 5809000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 2125000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 1125000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 3533000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 2142000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 1143000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 3468000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 22400000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 24290000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 23478000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 39094000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 38680000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 40256000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 204.38 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 107.50 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 339.00 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | 203.77 | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | 107.18 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 336.99 | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.571 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.626 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.581 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 2036000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 1451000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 4129000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -503000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -249000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -2690000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -1041000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -937000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -2414000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 12109000000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 10908000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 10643000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 122.90 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 65.16 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 11280177 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 11280177 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 11280177 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 11280177 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |